Characterization of single chain antibody targets through yeast two hybrid
© Vielemeyer et al; licensee BioMed Central Ltd. 2010
Received: 26 April 2010
Accepted: 22 August 2010
Published: 22 August 2010
Due to their unique ability to bind their targets with high fidelity, antibodies are used widely not only in biomedical research, but also in many clinical applications. Recombinant antibodies, including single chain variable fragments (scFv), are gaining momentum because they allow powerful in vitro selection and manipulation without loss of function. Regardless of the ultimate application or type of antibody used, precise understanding of the interaction between the antibody's binding site and its specific target epitope(s) is of great importance. However, such data is frequently difficult to obtain.
We describe an approach that allows detailed characterization of a given antibody's target(s) using the yeast two-hybrid system. Several recombinant scFv were used as bait and screened against highly complex cDNA libraries. Systematic sequencing of all retained clones and statistical analysis allowed efficient ranking of the prey fragments. Multiple alignment of the obtained cDNA fragments provided a selected interacting domain (SID), efficiently narrowing the epitope-containing region.
Interactions between antibodies and their respective targets were characterized for several scFv. For AA2 and ROF7, two conformation-specific sensors that exclusively bind the activated forms of the small GTPases Rab6 and Rab1 respectively, only fragments expressing the entire target protein's core region were retained. This strongly suggested interaction with a non-linear epitope. For two other scFv, TA10 and SF9, which recognize the large proteins giantin and non-muscle myosin IIA, respectively, precise antibody-binding regions within the target were defined. Finally, for some antibodies, secondary targets within and across species could be revealed.
Our method, utilizing the yeast two-hybrid technology and scFv as bait, is a simple yet powerful approach for the detailed characterization of antibody targets. It allows precise domain mapping for linear epitopes, confirmation of non-linear epitopes for conformational sensors, and detection of secondary binding partners. This approach may thus prove to be an elegant and rapid method for the target characterization of newly obtained scFv antibodies. It may be considered prior to any research application and particularly before any use of such recombinant antibodies in clinical medicine.
Because of their unique ability to recognize target antigens with extremely high fidelity, antibodies remain an essential tool in fundamental biomedical research and in clinical diagnostic testing. In addition, they represent one of the most promising novel therapeutic options, in particular in the field of cancer treatment. Worldwide, more than a thousand clinical trials have been completed and almost as many are currently underway using monoclonal antibodies as pharmaceuticals http://www.clinicaltrials.gov. Traditionally, monoclonal antibodies have been produced from hybridoma cell lines in a laborious process involving animal experimentation and screening large numbers of clones. More recently, recombinant monoclonal antibodies, which add an additional level of flexibility, have also become a viable treatment option for various human diseases [1–9]. Several alternatives to the classic in vivo selection of antibodies have been developed and refined (for summary see ). One of the most prominent technique is antibody phage display, which allows in vitro selection of single-chain variable fragment (scFv) antibodies from complex phage or phagemid libraries . In this approach, which has been utilized successfully in many laboratories, animal work is obviated entirely (for review see [12, 13]). It has been shown that scFv can even be manufactured for clinical use . In our own research laboratory, highly functional scFv antibodies that recognize a broad range of targets, including evolutionarily conserved proteins have been selected and characterized [15–18].
Regardless of the type of production or ultimate application, the effective use of antibodies depends on a detailed understanding of the underlying antibody-antigen interaction, i.e. knowledge about a given antibody's epitope(s). This holds true especially for clinical applications where such information would be of utmost importance to accurately predict wanted and unwanted (potentially harmful) biological effects. However, target characterization of both traditional and recombinant antibodies has been challenging. The gold standard of such epitope mapping - analysis of the crystal structure of a given antigen-antibody complex - is labor intensive and sometimes nearly impossible due to technical difficulties. Thus, often cumbersome strategies have to be developed, like systematic target protein mutagenesis or sub-fragment analysis. Examples of successful characterization of antibody targets through scanning mutagenesis and other techniques have been described elsewhere [19, 20]. More recently, combinatorial peptide phage display libraries have also been used [21, 22]. In the future, computer based or in silico combinatorial methods for epitope mapping, like Mapitope  might prove useful. Finally, epitope mapping has also become a powerful strategy in the process of developing new vaccines [24, 25].
Here we describe an alternative approach to characterize the interaction between antibodies and their respective targets. Time- and resource-demanding crystallography or mutagenesis experiments are circumvented. Instead the yeast two-hybrid (Y2H) technology is employed. In most two-hybrid applications in the recombinant antibody field, scFv are selected from a prey library , Here, the system is inverted: previously characterized scFv are used as bait and screened against a comprehensive cDNA library. This new approach yielded novel, detailed data about the targets of several recombinant antibodies, including the need for tertiary antigen structure for binding of conformational sensors, mapping of precise epitopes and unveiling of secondary targets.
Results and Discussion
Antibody targets are characterized using the two-hybrid system with the scFv antibody as bait, a validated scoring system to remove non-specific binders, and determination of selected interacting domains
Individual scFv antibodies were exposed to a cDNA library with full coverage, derived from either human placenta or from Drosophila. More than 50 million potential interactions were tested during each screen. Prey fragments of positive clones were identified using sequence analysis and comparison with GenBank databases using the BLAST algorithm . Next, a Predicted Biological Score (PBS) was computed for each clone as described before , enabling classification according to interaction reliability (Figure 1B). This permitted ranking of the clones into categories from "A" to "D" in decreasing probability of having a specific interaction with the scFv-bait. Two additional categories were designated: "E", interacting clones, which were likely retained due to highly connected prey domains; and "F", clones that were experimentally proven Y2 H artifacts. In a third step, overlapping prey fragments originating from the same gene were designated as clusters and their translated amino acid sequences were aligned and superimposed onto the open reading frame (Figure 1C). Overlapping regions shared by all fragments were designated as "selected interacting domain" (SID), as described before .
For the conformation-specific antibodies AA2 and ROF7, only large fragments are obtained, suggesting a non-linear antibody binding-site
The result of the Drosophila screen suggested that AA2, which had been selected against human Rab6a, can also recognize the fly Rab6a homologue. In our experience, polyclonal anti-Rab6 antibodies (generated by immunizing rabbits with the full-length mammalian protein) have failed to label dRab6 in immunofluorescence (unpublished observations). In contrast, and in agreement with the Y2 H data, AA2 labeling of dRab6 on Golgi membranes was seen by immunofluorescence (Figure 2B, a-c). Furthermore, analogous to what had been shown in mammalian cells , AA2 was also functional as an intrabody and labeled Golgi stacks in living Drosophila S2 cells (Figure 2B, d-f). Our Y2 H approach thus revealed that in addition to mammalian Rab6, AA2 also detects the Drosophila homologue. This is likely due to the fact that the three-dimensional structure of GTP-bound Rab6 remained highly conserved throughout evolution.
In the two Y2 H screens using conformational sensors as bait (AA2 and ROF7) and comprehensive prey libraries, only targets expressing a sizable portion of the protein (amino acids 2-178 for Rab1a, and 13-174 for Rab6a) were retained. Likely, fragments had to be large enough to allow folding into proper tertiary structure and GTP loading. The first few amino-terminal residues and the last 30 or so amino-acid long carboxy-terminal hypervariable tail are known to be dispensable for correct three-dimensional assembly of small GTPases. In fact, the crystal structure of Rab6b was solved by expressing a recombinant protein that contained only the core region of the protein (amino acids 6-181) . We believe that the residues, which make up the epitopes for the binding of AA2 and ROF7, respectively, are non-adjacent in the primary amino acid sequence and only come together after correct folding of the polypeptide into tertiary structure and subsequent activation through GTP binding. Lack of reactivity of both antibodies on immunoblotting, and results from the Y2 H screens strongly supports this hypothesis.
In summary, our approach showed that for the conformation-specific sensors AA2 and ROF7 correct three-dimensional antigen structures are needed to present the antibody binding sites. It furthermore revealed that the AA2 epitope is conserved in evolution since dRab6 is recognized by the scFv.
For the anti-giantin antibody TA10, a small binding site within the large coiled-coil protein giantin is determined
Next, we characterized the target of TA10. This scFv is a recombinant antibody directed against a very large (>350 kDa) Golgi-associated matrix protein called giantin. TA10 was originally selected via phage display using intact, purified, Golgi stacks as target .
In summary, the Y2 H screen enabled rapid and accurate target characterization for TA10. A precise region of 79 amino acids, representing less than 2.5% of the entire protein, was determined as its binding site.
For the non-muscle myosin IIA-targeting antibody SF9, a precise epitope within a long coiled-coil protein is determined and cross reactivity with human and other, non-human, homologues is revealed
SF9 was selected alongside TA10 in a phage display screen using purified rat liver Golgi stacks as the antigen. SF9's target, non-muscle myosin IIA, was identified using immunoblotting followed by mass spectrometry analysis .
Non-muscle myosins are evolutionarily conserved proteins. In addition, SF9 was found to bind to a region of the protein that shares near-identical amino acid sequences between human homologues (Figure 6D). Alignment of the SID with non-muscle myosins of other species revealed a high degree of evolutionary conservation in this region even with the Drosophila counterpart (Figure 7D). We thus speculated that SF9 might also detect the insect form of myosin. Indeed, when using total insect cell lysates a single ca. 200-kDa-large band was detected by SF9. This signal completely disappeared after specific anti-myosin RNAi-mediated gene silencing (Figure 7E).
In summary, our Y2H-approach allowed precise characterization of the SF9 target, defining a very small (<3kDa) epitope within a ~200kDa protein. In addition, it revealed cross-reactivity with closely related proteins of the same and across species.
Results of screens using antibodies that do not work as intrabodies
Our novel approach yielded important additional information about the targets of several distinct monoclonal antibodies. However, some variability in the strength and reliability of the data could be noted when comparing individual screens. For instance, when screening using yet another scFv, named F2C (an antibody which binds α-tubulin ), results were less conclusive. While a total of 380 interacting clones were obtained, only 4 encoded for α-tubulin (data not shown). Their alignment allowed narrowing of the epitope-containing region to the C-terminal portion of the protein. However, many of the remaining 376 clones were also classified as possible binders using the PBS scoring method. Nonetheless, it is unlikely that they represent secondary targets for F2C given a highly specific signal of F2C in both immunofluorescence and Western blotting . Another scFv originating from the above mentioned Golgi-stack screen, called TE5 , was tested in our approach. While many interacting clones were retained, none could be confirmed in overexpression experiments and the TE5 target remained elusive so far (data not shown). In sharp contrast to the just mentioned examples (F2C, TE5) our ROF7- and SF9-screens not only confirmed the antibodies' targets but also gave detailed information about their respective epitopes: in each case almost 90% of clones aligned within its target(s) (see Figures 3 and 6). In agreement with the more classical use of scFv in Y2 H  there seems to be a direct correlation between the ability of an antibody to fold correctly under the reducing conditions of the eukaryotic (yeast or mammalian) cytosol and their use in Y2 H. While SF9, TA10, AA2 and ROF7 efficiently bind their respective targets when expressed as intrabodies, F2C is only faintly staining microtubules in living cells and TE5 never yielded specific staining as an intrabody. We thus hypothesize that the same relative efficiency for target recognition is present during the yeast two hybrid experiments. To make full use of our method, it will therefore be important to obtain good intrabodies, for example via screening of dedicated libraries [35, 36] or through the use of single domain antibodies, like camelidae antibodies, that seem to be more resistant to the reducing conditions of the intracellular milieu .
We present a novel approach, which allows in-depth characterization of antibody target(s) using the Y2 H technology. In our approach the traditional orientation of prey and bait is reversed, complex cDNA prey libraries are screened, and a robust scoring system to eliminate non-specific binders is employed. This way, critical new information about antibodies' targets can be obtained. This includes strong corroborative evidence for conformational specificity and the need for a non-linear epitope for conformational antibodies, precise mapping of small epitopes, and information about cross reactivity within and across species.
In summary, our Y2 H approach represents a powerful method for the detailed characterization of scFv/antibody targets. Given the high quantity and quality of new data that can be obtained from a simple experiment, we believe that our approach might in the future serve as an invaluable tool for the detailed target characterization of many types of antibodies.
Preparation of bait vectors, Y2 H cloning strategy, Y2 H screens
The plasmids pHEN2 containing the ORF for the previously described and characterized scFv (AA2, TA10, and SF9) [16, 17] as well as the anti Rab1 scFv ROF7 (unpublished data), were used for sub-cloning (via use of the restriction enzymes NcoI and NotI) into a pBTM116 derived bait vector as described . The generation of random-primed human placenta and drosophila cDNA libraries in SfiI polilynker adapted pGADGH plasmid has been described previously as well [33, 39]. In such libraries, inserts have an average size of between 700 (drosophila) and 800 (human placenta) base pairs and the complexity reaches over 50 million clones in E. coli. The DNA of a maxiprep (Quiagen) prepared from E. coli scraped colonies was transformed into yeast strain Y187 using the classical lithium acetate protocol and plated on four hundred 140 mm Petri plates. Conditions were optimized by determining the linearity of colony forming unit (cfu) as a function of DNA concentration to avoid the transformation of individual yeast cells with multiple plasmids, because this could lead to the identification of false positive clones. After colony formation, the four hundred dishes were scraped. The resulting cells were pooled, then aliquoted and stored in glycerol 40% at -80°C as equivalent fractions of the same library. Screens were performed using a cell-to-cell mating method described previously . Briefly: four hundred million prey cells were mixed with eight hundred million bait cells and spread on YDP plates for four hour to ensure mating but avoid replication of the already formed diploid cells. This ensures a complete coverage of the highly complex library because a minimum of fifty million clones is tested (10 times the primary complexity of the yeast transformed cDNA library). The genetic saturation of the screens allows statistical analysis of the results of each screen . In addition, the use of the same library for many screens permits the identification of fragments that are highly connected and thus are potential "false positives" . Qualitative comparison of lacZ reporter activation was done by standard X-Gal Top agar overlay assay. For details of the analysis of obtained clones see firsts paragraph "Results and Discussion" section. Lists of specifically interacting clones for each screen that are not provided in this manuscript in Additional files 1 through 5 can be requested from the corresponding author.
Cloning of expression plasmids for confirmation of predicted epitopes
For expression of the scFv AA2 fused to the Green fluorescent protein (GFP) in insect cells the mammalian expression plasmid (pEGFP-N3NN-AA2, ) was digested with EcoRI and XbaI. The released fragment was then cloned into identical sites within the drosophila expression vector pMT/V5 (Invitrogen).
For TA10 related experiments an untagged full-length giantin expression plasmid (pSG5-GCP364) was received as a kind gift from Yoshio Misumi (Fukuoka, Japan). The mammalian expression plasmid giantin ΔTABD was generated by removing a 702-nucleotide long piece by cutting (and subsequently religating) with PmlI within the ORF of giantin of the plasmid pSG5-GCP364. For the generation of the plasmid giantin-TA10BDshort the following primers were used for PCR: Forward 5'- CCC AAG CTT TGT GAG CTA AAG AAG CAG CC -3' and Reverse 5'- CGG GAT CCT TAC TTT CCT AGG AGT GCA TC -3'. For giantin-79aa control the following primers were used for PCR: Forward 5'- CCC AAG CTT AGC CAG GTT TCT GTT CAG AAT -3' and Reverse 5'- CGG GAT CCT TAT TCG GTG CTC TCT GCA ATC TT -3'. For both PCR reactions pSG5-GCP364 was used as the template. Amplified segments were digested with HindIII and BamHI (visualized in Italics in the primers) and inserted into a pEGFP expression vector prepared by digestion with the same enzymes.
For experiments regarding scFv SF9 we obtained the expression plasmid containing the full-length non-muscle myosin heavy chain IIA (pTRE GFP NMHCIIA) from Robert Adelstein (National Institutes of Health Bethesda, MD, U.S.A.) via Addgene®. NMHCIIA-ΔC-ter was generated by digesting pTRE GFP NMHCIIA with EcoRI and SpeI, blunting with Klenow and religating, thus creating a truncated fusion protein lacking the last 620 aa of MNHCIIA. In order to remove only the 29 amino acid long putative SF9 binding domain in its C-terminal portion the following multi-step strategy was used: (i) PCR amplification of a NMHCIIA fragment ranging from the end of the putative SF9 binding domain until beyond the unique SacII site creating a KpnI site at the 5'-end using the following primers: Forward1 5'-GGG GTA CCA TGA AGG CCC AGT TCG AGC GG-3' (KpnI site in Italics), Reverse1 5'-AGG TCG GTG TTG ATC TGG TC-3'; (ii) insertion of the digested PCR product (PCR I) into the pEGFP-C1 vector (Clontech) equally digested with KpnI and SacII; (iii) a second PCR amplification (PCR II) using the same NMHCIIA-template, a forward primer before the unique EcoRI site (Forward2 5'-AAA GGG GAC TCG GAG CAC-3') and a reverse primer annealing just before the beginning of the putative SF9 binding domain again containing a KpnI site in frame (Reverse2 5'-GGG GTA CCC TCC ACC TGC TGC TCT AGG GC-3', KpnI site in Italics); (iv) digestion of both, the PCR II product as well as the pEGFP-C1 vector containing PCR I with KpnI and EcoRI and insertion of the former into the latter creating the plasmid pEGFP-fragment-ΔSF9BD (non muscle myosin heavy chain II A fragment delta SF9 binding domain). In a separate reaction the original pTRE-GFP-NMHCIIA as well as the empty plasmid pEGFP-C1 were digested with EcoRI and SacII and the 1055 bp MYH9 fragment was inserted in frame with GFP creating the plasmid pEGFP-fragment. All constructs were verified by sequencing.
Cell cultures, immunofluorescence and immunoblotting analyses
HeLa cells were grown under standard conditions and transfected as described . For immunofluorescence respective scFv (AA2, TA10, SF9) were first converted to dimeric mini-antibodies (hAA2, hTA10, hSF9) by adding a human Fc portion as described before . For immunofluorescence experiments cells were then incubated with secondary anti-human antibodies (Jackson ImmunoResearch Laboratories, Westgrove, PA, USA and Molecular Probes, Eugene, OR, USA). For immunoblotting, total cell lysates of transfected HeLa cells were boiled in sample buffer and subjected to SDS-PAGE. After transfer onto nitrocellulose, membranes were blocked and then incubated with mouse anti-GFP antibodies (Roche Diagnostics GmbH, Mannheim Germany), with the humanized scFv hSF9 or with mouse anti α-tubulin antibodies (B-5-1-2, Sigma Aldrich) and revealed with ECL after incubation with respective secondary antibodies coupled with horseradish peroxidase. Transfection of the fragment constructs with a predicted molecular weight of ~70 kDa (see details in Figure 4C) were used for immunoblotting, since non-muscle myosin is present abundantly in HeLa cells and it is difficult to visualize the overexpressed protein as an additional band given the size of non-muscle myosin heavy chain (~200kDa).
Drosophila S2 and S2R cells were grown and prepared for transfection and immunofluorescence as described elsewhere . Briefly, S2 cells were plated into 24-well plates (BD Falcon) at 160,000 cells/well in 1 mL growth medium (Schneider's Drosophila medium (GIBCO, supplemented with 10% heat inactivated fetal calf serum). Cells were subsequently transfected with plasmid DNA using the CaPO4 method . The following day, transfected cells were plated on glass cover slips coated with concavalin A and after 20 minutes fixed for 5 min with 4% paraformaldehyde in PBS or with 100% methanol at -20°C. Incubation with primary and secondary antibodies of transfected or non-transfected S2 and S2R cells was performed as described above for HeLa cells.
For knock down of zipper (myosin II homologue in drosophila) dsRNAs were prepared as described using the following primers: left primer: 5'-CCT AAA GCC ACT GAC AAG ACG-3' right primer: 5'-CGG TAC AAG TTC GAG TCA AGC-3' creating a PCR product of 647 bp. T7 sites were added symmetrically and processed as before .
Gap Repair for TA10 Epitope determination
Seventeen PCR fragments of different size were generated using as matrix the A-135 prey clone (Additional file 4). At the extremity of each fragment, 50 nucleotides corresponding to the polylinker of the prey vector were added to allow "gap repair" recombination. The transformation of the two-hybrid yeast strain containing TA10 bait plasmid with the PCR product and a digested prey plasmid resulted in the production of yeast transformants containing the bait and different prey fragments. The interactions of the prey fragment were tested by spotting in minus histidine media and by β-galactosidase qualitative observation. All fragments were aligned along the ORF of giantin.
The authors greatly acknowledge the Nikon Imaging Centre @ Institut Curie-CNRS and the PICT-IBiSA Imaging Facility of the Curie Institute, Paris for technical support, and Sandrine Moutel for her invaluable help and advice.
The project was supported by the French Agence Nationale de la Recherche ("ANR") BiotecS-ANR-09-BIOT-005 (FP and JCR). The work was also supported by the ANR program Blanc, ANR-06-BLANC-0107 (BG and FP), by the Human Science Frontier Organization (FP), by the Curie Institute, Paris, France, and by the Centre National de la Recherche Scientifique (CNRS) of France.
The full-length giantin expression plasmid (pSG5-GCP364) was received as a kind gift from Yoshio Misumi (Fukuoka, Japan).
- Adams GP, Weiner LM: Monoclonal antibody therapy of cancer. Nat Biotechnol. 2005, 23 (9): 1147-1157. 10.1038/nbt1137.View ArticleGoogle Scholar
- Deonarain MP: Recombinant antibodies for cancer therapy. Expert Opin Biol Ther. 2008, 8 (8): 1123-1141. 10.1517/147125126.96.36.1993.View ArticleGoogle Scholar
- Maggon K: Monoclonal antibody "gold rush". Curr Med Chem. 2007, 14 (18): 1978-1987. 10.2174/092986707781368504.View ArticleGoogle Scholar
- Nelson AL, Reichert JM: Development trends for therapeutic antibody fragments. Nat Biotechnol. 2009, 27 (4): 331-337. 10.1038/nbt0409-331.View ArticleGoogle Scholar
- O'Brien S, Albitar M, Giles FJ: Monoclonal antibodies in the treatment of leukemia. Curr Mol Med. 2005, 5 (7): 663-675. 10.2174/156652405774641089.View ArticleGoogle Scholar
- Presta LG: Selection, design, and engineering of therapeutic antibodies. J Allergy Clin Immunol. 2005, 116 (4): 731-736. 10.1016/j.jaci.2005.08.003. quiz 737View ArticleGoogle Scholar
- Reichert JM, Valge-Archer VE: Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov. 2007, 6 (5): 349-356. 10.1038/nrd2241.View ArticleGoogle Scholar
- Schaedel O, Reiter Y: Antibodies and their fragments as anti-cancer agents. Curr Pharm Des. 2006, 12 (3): 363-378. 10.2174/138161206775201983.View ArticleGoogle Scholar
- Weiner GJ: Monoclonal antibody mechanisms of action in cancer. Immunol Res. 2007, 39 (1-3): 271-278. 10.1007/s12026-007-0073-4.View ArticleGoogle Scholar
- Filpula D: Antibody engineering and modification technologies. Biomol Eng. 2007, 24 (2): 201-215. 10.1016/j.bioeng.2007.03.004.View ArticleGoogle Scholar
- Smith GP: Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science. 1985, 228 (4705): 1315-1317. 10.1126/science.4001944.View ArticleGoogle Scholar
- Hoogenboom HR: Overview of antibody phage-display technology and its applications. Methods Mol Biol. 2002, 178: 1-37.Google Scholar
- Kretzschmar T, von Ruden T: Antibody discovery: phage display. Curr Opin Biotechnol. 2002, 13 (6): 598-602. 10.1016/S0958-1669(02)00380-4.View ArticleGoogle Scholar
- Weisser NE, Hall JC: Applications of single-chain variable fragment antibodies in therapeutics and diagnostics. Biotechnol Adv. 2009, 27 (4): 502-520. 10.1016/j.biotechadv.2009.04.004.View ArticleGoogle Scholar
- Dimitrov A, Quesnoit M, Moutel S, Cantaloube I, Pous C, Perez F: Detection of GTP-tubulin conformation in vivo reveals a role for GTP remnants in microtubule rescues. Science. 2008, 322 (5906): 1353-1356. 10.1126/science.1165401.View ArticleGoogle Scholar
- Nizak C, Martin-Lluesma S, Moutel S, Roux A, Kreis TE, Goud B, Perez F: Recombinant antibodies against subcellular fractions used to track endogenous Golgi protein dynamics in vivo. Traffic. 2003, 4 (11): 739-753. 10.1034/j.1600-0854.2003.00132.x.View ArticleGoogle Scholar
- Nizak C, Monier S, del Nery E, Moutel S, Goud B, Perez F: Recombinant antibodies to the small GTPase Rab6 as conformation sensors. Science. 2003, 300 (5621): 984-987. 10.1126/science.1083911.View ArticleGoogle Scholar
- Nizak C, Sougrat R, Jollivet F, Rambourg A, Goud B, Perez F: Golgi inheritance under a block of anterograde and retrograde traffic. Traffic. 2004, 5 (4): 284-299. 10.1111/j.1398-9219.2004.0174.x.View ArticleGoogle Scholar
- Frillingos S, Sahin-Toth M, Wu J, Kaback HR: Cys-scanning mutagenesis: a novel approach to structure function relationships in polytopic membrane proteins. Faseb J. 1998, 12 (13): 1281-1299.Google Scholar
- Rimon A, Hunte C, Michel H, Padan E: Epitope Mapping of Conformational Monoclonal Antibodies Specific to NhaA Na(+)/H(+) Antiporter: Structural and Functional Implications. J Mol Biol. 2008, 379 (3): 471-481. 10.1016/j.jmb.2008.03.067.View ArticleGoogle Scholar
- Mayrose I, Penn O, Erez E, Rubinstein ND, Shlomi T, Freund NT, Bublil EM, Ruppin E, Sharan R, Gershoni JM, et al: Pepitope: epitope mapping from affinity-selected peptides. Bioinformatics. 2007, 23 (23): 3244-3246. 10.1093/bioinformatics/btm493.View ArticleGoogle Scholar
- Mayrose I, Shlomi T, Rubinstein ND, Gershoni JM, Ruppin E, Sharan R, Pupko T: Epitope mapping using combinatorial phage-display libraries: a graph-based algorithm. Nucleic Acids Res. 2007, 35 (1): 69-78. 10.1093/nar/gkl975.View ArticleGoogle Scholar
- Bublil EM, Freund NT, Mayrose I, Penn O, Roitburd-Berman A, Rubinstein ND, Pupko T, Gershoni JM: Stepwise prediction of conformational discontinuous B-cell epitopes using the Mapitope algorithm. Proteins. 2007, 68 (1): 294-304. 10.1002/prot.21387.View ArticleGoogle Scholar
- Rinaudo CD, Telford JL, Rappuoli R, Seib KL: Vaccinology in the genome era. J Clin Invest. 2009, 119 (9): 2515-2525. 10.1172/JCI38330.View ArticleGoogle Scholar
- Sette A, Peters B: Immune epitope mapping in the post-genomic era: lessons for vaccine development. Curr Opin Immunol. 2007, 19 (1): 106-110. 10.1016/j.coi.2006.11.002.View ArticleGoogle Scholar
- Visintin M, Tse E, Axelson H, Rabbitts TH, Cattaneo A: Selection of antibodies for intracellular function using a two-hybrid in vivo system. Proc Natl Acad Sci USA. 1999, 96 (21): 11723-11728. 10.1073/pnas.96.21.11723.View ArticleGoogle Scholar
- Biocca S, Neuberger MS, Cattaneo A: Expression and targeting of intracellular antibodies in mammalian cells. Embo J. 1990, 9 (1): 101-108.Google Scholar
- Visintin M, Settanni G, Maritan A, Graziosi S, Marks JD, Cattaneo A: The intracellular antibody capture technology (IACT): towards a consensus sequence for intracellular antibodies. J Mol Biol. 2002, 317 (1): 73-83. 10.1006/jmbi.2002.5392.View ArticleGoogle Scholar
- Visintin M, Meli GA, Cannistraci I, Cattaneo A: Intracellular antibodies for proteomics. J Immunol Methods. 2004, 290 (1-2): 135-153. 10.1016/j.jim.2004.04.014.View ArticleGoogle Scholar
- Visintin M, Quondam M, Cattaneo A: The intracellular antibody capture technology: towards the high-throughput selection of functional intracellular antibodies for target validation. Methods. 2004, 34 (2): 200-214. 10.1016/j.ymeth.2004.04.008.View ArticleGoogle Scholar
- Feldhaus MJ, Siegel RW: Yeast display of antibody fragments: a discovery and characterization platform. J Immunol Methods. 2004, 290 (1-2): 69-80. 10.1016/j.jim.2004.04.009.View ArticleGoogle Scholar
- Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ: Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 1997, 25 (17): 3389-3402. 10.1093/nar/25.17.3389.View ArticleGoogle Scholar
- Formstecher E, Aresta S, Collura V, Hamburger A, Meil A, Trehin A, Reverdy C, Betin V, Maire S, Brun C, et al: Protein interaction mapping: a Drosophila case study. Genome Res. 2005, 15 (3): 376-384. 10.1101/gr.2659105.View ArticleGoogle Scholar
- Garcia-Saez I, Tcherniuk S, Kozielski F: The structure of human neuronal Rab6b in the active and inactive form. Acta Crystallogr D Biol Crystallogr. 2006, 62 (Pt 7): 725-733. 10.1107/S0907444906015319.View ArticleGoogle Scholar
- der Maur AA, Zahnd C, Fischer F, Spinelli S, Honegger A, Cambillau C, Escher D, Pluckthun A, Barberis A: Direct in vivo screening of intrabody libraries constructed on a highly stable single-chain framework. J Biol Chem. 2002, 277 (47): 45075-45085. 10.1074/jbc.M205264200.View ArticleGoogle Scholar
- Philibert P, Stoessel A, Wang W, Sibler AP, Bec N, Larroque C, Saven JG, Courtete J, Weiss E, Martineau P: A focused antibody library for selecting scFvs expressed at high levels in the cytoplasm. BMC Biotechnol. 2007, 7: 81-10.1186/1472-6750-7-81.View ArticleGoogle Scholar
- Rothbauer U, Zolghadr K, Tillib S, Nowak D, Schermelleh L, Gahl A, Backmann N, Conrath K, Muyldermans S, Cardoso MC, et al: Targeting and tracing antigens in live cells with fluorescent nanobodies. Nat Methods. 2006, 3 (11): 887-889. 10.1038/nmeth953.View ArticleGoogle Scholar
- Vojtek AB, Hollenberg SM: Ras-Raf interaction: two-hybrid analysis. Methods Enzymol. 1995, 255: 331-342. full_text.View ArticleGoogle Scholar
- Colland F, Daviet L: Integrating a functional proteomic approach into the target discovery process. Biochimie. 2004, 86 (9-10): 625-632. 10.1016/j.biochi.2004.09.014.View ArticleGoogle Scholar
- Fromont-Racine M, Rain JC, Legrain P: Building protein-protein networks by two-hybrid mating strategy. Methods Enzymol. 2002, 350: 513-524. full_text.View ArticleGoogle Scholar
- Moutel S, El Marjou A, Vielemeyer O, Nizak C, Benaroch P, Dubel S, Perez F: A multi-Fc-species system for recombinant antibody production. BMC Biotechnol. 2009, 9: 14-10.1186/1472-6750-9-14.View ArticleGoogle Scholar
- Echard A, Hickson GR, Foley E, O'Farrell PH: Terminal cytokinesis events uncovered after an RNAi screen. Curr Biol. 2004, 14 (18): 1685-1693. 10.1016/j.cub.2004.08.063.View ArticleGoogle Scholar
- Jordan M, Schallhorn A, Wurm FM: Transfecting mammalian cells: optimization of critical parameters affecting calcium-phosphate precipitate formation. Nucleic Acids Res. 1996, 24 (4): 596-601. 10.1093/nar/24.4.596.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.